Despite the worse than anticipated results, Huang said the Sinovac vaccine would still be "usable" by helping to relieve pressures on healthcare systems while reducing potential deaths, given its higher efficacy for moderate and severe cases that would require medical treatment.However, its low overall efficacy could hinder Sinovac's ability to expand its market share globally, Huang said.